Edition:
United States

Infinity Pharmaceuticals Inc (INFI.O)

INFI.O on Nasdaq

2.18USD
22 Jan 2018
Change (% chg)

$0.14 (+6.86%)
Prev Close
$2.04
Open
$2.05
Day's High
$2.24
Day's Low
$2.00
Volume
945,575
Avg. Vol
2,166,707
52-wk High
$3.84
52-wk Low
$0.93

Latest Key Developments (Source: Significant Developments)

Infinity Expects Net Loss For 2018 To Range From $40 Mln To $50 Mln​
Monday, 8 Jan 2018 08:32am EST 

Jan 8 (Reuters) - Infinity Pharmaceuticals Inc ::INFINITY PHARMACEUTICALS INC - ‍INFINITY EXPECTS NET LOSS FOR 2018 TO RANGE FROM $40 MILLION TO $50 MILLION​.INFINITY PROVIDES UPDATE ON IPI-549 PHASE 1/1B STUDY, 2018 GOALS AND FINANCIAL GUIDANCE.INFINITY PHARMACEUTICALS INC - ‍INFINITY EXPECTS TO END 2018 WITH A YEAR-END CASH AND INVESTMENTS BALANCE RANGING FROM $10 MILLION TO $20 MILLION​.INFINITY PHARMACEUTICALS INC - EXPECTS TO END 2018 WITH A YEAR-END CASH AND INVESTMENTS BALANCE RANGING FROM $10 MILLION TO $20 MILLION.INFINITY PHARMACEUTICALS INC - ‍INFINITY ENDED 2017 WITH APPROXIMATELY $57.6 MILLION IN CASH AND INVESTMENTS​.  Full Article

Infinity Q3 loss per share $0.14
Tuesday, 7 Nov 2017 08:01am EST 

Nov 7 (Reuters) - Infinity Pharmaceuticals Inc ::Infinity provides company update and reports third quarter 2017 financial results.Q3 loss per share $0.14.Q3 earnings per share view $-0.21 -- Thomson Reuters I/B/E/S.Q3 revenue $6.0 million.Q3 revenue view $14.7 million -- Thomson Reuters I/B/E/S.Infinity Pharmaceuticals Inc - ‍infinity expects net loss for 2017 to range from $40 million to $50 million​.Infinity Pharmaceuticals - ‍expects to end 2017 with a cash, cash equivalents and available-for-sale securities balance ranging from $40 million to $50 million​.  Full Article

Infinity Pharmaceuticals and Bristol-Myers Squibb expand clinical collaboration
Monday, 25 Sep 2017 08:02am EDT 

Sept 25 (Reuters) - Bristol-Myers Squibb Co :Infinity Pharmaceuticals and Bristol-Myers Squibb expand clinical collaboration evaluating ipi-549 in combination with Opdivo (nivolumab).Infinity Pharmaceuticals Inc - ‍combination dose-escalation is also ongoing, and combination expansion is expected to begin in second half of 2017​.Infinity Pharmaceuticals Inc - ‍patient enrollment is complete in monotherapy dose-escalation, and monotherapy expansion is ongoing​.Infinity Pharmaceuticals- deal expands Phase 1/1b study to include patients with triple negative breast cancer who havent been previously exposed to anti-PD-1/anti-PD-l1 therapy​.  Full Article

Infinity Q2 loss per share $0.34
Thursday, 3 Aug 2017 04:05pm EDT 

Aug 3 (Reuters) - Infinity Pharmaceuticals Inc ::Infinity provides company update and reports second quarter 2017 financial results.Q2 loss per share $0.34.Q2 earnings per share view $-0.20 -- Thomson Reuters I/B/E/S.Infinity Pharmaceuticals Inc - ‍expects net loss for 2017 to range from $40 million to $50 million​.Infinity Pharmaceuticals- ‍expects existing cash,cash equivalents at june 30, 2017, will be adequate to satisfy company's capital needs into q1 of 2019​.  Full Article

Infinity amends PI3K-Delta,Gamma Agreement with Takeda Oncology
Thursday, 27 Jul 2017 11:21am EDT 

July 27 (Reuters) - Infinity Pharmaceuticals Inc ::Infinity amends PI3K-Delta,Gamma Agreement with Takeda Oncology.Co says it has amended its license agreement with Takeda Oncology for IPI-549.Co will no longer have obligation to pay Takeda on worldwide net sales of selective inhibitors of PI3K-Gamma.Co remains obligated to pay development, regulatory and commercial milestones to Takeda for IPI-549.  Full Article

Infinity reports Q1 loss per share $0.21
Tuesday, 9 May 2017 04:02pm EDT 

May 9 (Reuters) - Infinity Pharmaceuticals Inc :Infinity provides company update and reports first quarter 2017 financial results.Q1 loss per share $0.21.Q1 earnings per share view $-0.27 -- Thomson Reuters I/B/E/S.Infinity Pharmaceuticals Inc - Infinity expects net loss for 2017 to range from $40 million to $50 million..  Full Article

Infinity expects net loss for 2017 to range from $40 mln-$50 mln
Tuesday, 14 Mar 2017 04:05pm EDT 

Infinity Pharmaceuticals Inc : Infinity provides company update and reports fourth quarter 2016 financial results . Infinity Pharmaceuticals Inc- expects net loss for 2017 to range from $40 million to $50 million . Infinity Pharmaceuticals- expects to end 2017 with year-end cash, cash equivalents, available-for-sale securities balance ranging from $40 million-$50 million .Infinity Pharma- expects existing cash, cash equivalents, available-for-sale securities at Dec. 31, 2016, adequate to satisfy capital needs into Q1 2019.  Full Article

Infinity expects net loss for 2017 in the range of $40 mln to $50 mln
Monday, 9 Jan 2017 08:03am EST 

Infinity Pharmaceuticals Inc : Infinity provides 2017 goals and financial guidance . Infinity Pharmaceuticals Inc - expects to end 2017 with a year-end cash and investments balance ranging from $40 million to $50 million . Infinity Pharmaceuticals Inc - expects net loss for 2017 to range from $40 million to $50 million. . Infinity Pharmaceuticals - updated cash runway expectation assumes receiving $6.0 million milestone payment from verastem for positive duo study results .Infinity Pharmaceuticals sees existing cash, cash equivalents, available-for-sale securities at Dec 31 2016 to be adequate to satisfy capital needs into Q1 2019.  Full Article

Infinity Pharma Q2 earnings per share $1.05
Tuesday, 9 Aug 2016 04:01pm EDT 

Infinity Pharmaceuticals Inc : Q2 earnings per share $1.05 . Q2 revenue $9.5 million . Infinity provides company update and reports second quarter 2016 financial results . Q2 earnings per share view $-0.89 -- Thomson Reuters I/B/E/S . Q2 revenue view $13.9 million -- Thomson Reuters I/B/E/S . Continuing to explore a broad range of strategic options for duvelisib, including a potential sale of program . "in parallel, company continues to advance key value drivers for duvelisib" . Infinity is also proceeding with its planned development of ipi-549 in multiple solid tumors .Duo study of duvelisib compared to ofatumumab in 319 patients with relapsed or refractory cll, will proceed to final analysis.  Full Article

Infinity Pharmaceuticals sees workforce restructuring completed by year-end
Tuesday, 28 Jun 2016 08:22am EDT 

Infinity Pharmaceuticals Inc : Expects to incur severance, benefits and related costs of about $8 million . Says currently expects clinical trial and related development close down costs to range from $5 million to $7 million . Says company expects related cash outlays to be paid during year ended December 31, 2016 - SEC filing .Expects workforce restructuring to be substantially completed by July 15, 2016 ; to be fully completed by December 31, 2016.  Full Article

BRIEF-Infinity Expects Net Loss For 2018 To Range From $40 Mln To $50 Mln​

* INFINITY PHARMACEUTICALS INC - ‍INFINITY EXPECTS NET LOSS FOR 2018 TO RANGE FROM $40 MILLION TO $50 MILLION​